MRC1 and neoplasm: CD206+ M2 TAMs conventionally considered to be tumor-promoting have been shown to be capable of antigen cross-presentation, stimulation of antitumor immune responses, and tumor regression in mouse models of melanoma and colorectal cancer, due to concurrent CD80 expression (7).